timothy sykes logo

Stock News

ImmunityBio Stock Surges 22% as Revenue and Trials Impress Investors

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 1/16/2026, 9:18 am ET 1/16/2026, 9:18 am ET | 4 min 4 min read
ImmunityBio Stock Surges 22% as Revenue and Trials Impress Investors Thumbnail

ImmunityBio Inc. stocks surged 18.91% after promising clinical trial outcomes bolstered investor confidence in their innovative therapies.

Candlestick Chart

Live Update At 09:18:04 EST: On Friday, January 16, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 18.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

It’s been a rollercoaster for ImmunityBio, but the ride seems to be going up. The company’s revenue skyrocketed, posting a significant increase of approximately 700% in 2025. They’ve pulled a ton of attention with this massive leap. In the last few months alone, particularly from October to December, revenues touched $38.3 million. Compare that with the same period in 2024, and we’re looking at a 431% jump! This isn’t just a fluke; it’s a sign of robust growth.

The sharper end of the financial needle points toward other key metrics as well. The quarter-over-quarter unit sales grew at a robust pace of 54%. Investors must be thinking, “Get me some of that!” and are promptly betting on ImmunityBio’s future prospects.

Investor Confidence on the Rise

It’s hard to ignore the buzz in the boardrooms following ImmunityBio’s announcement on Saudi FDA’s approval of its product, ANKTIVA. Here is a treatment approved for non-muscle invasive bladder cancer. That’s a big deal—not just for patients but for the company’s expanding market footprint.

The Middle East isn’t just a dot on the map anymore. It’s a hot venture ground for ImmunityBio, and they’re doubling down. They’ve even set the stage with a new office here to ensure that their strategic expansions are grounded in infrastructure and real market assets.

There’s also a win showcasing Saudi FDA’s go-ahead for ANKTIVA in combination with immune checkpoint inhibitors. By doing so, they’ve practically unlocked a new level of treatment landscape against metastatic non-small cell lung cancer. The first of its kind, combining IL-15 receptor superagonistics with checkpoint inhibitors—all without the sword of chemotherapy hanging over patients’ heads. Investors smell potential with a side of relief for patients, and they are acting on it.

More Breaking News

Conclusion

ImmunityBio continues its upward march, with financials and strategic maneuvers holding hands to great effect. Stock prices whipping up by about 22% might very well be a bellwether to more climbs down the road. In just a day, it leaped from $3.02 to $3.95, signaling market optimism in response to robust revenue reports and medicinal approvals.

The company’s financial finesse ties directly into their buoyant news. Whether it’s financial metrics that read like gold tickets or approvals that smash open doors to new markets, ImmunityBio has more than just left a mark—it’s set a new course. Venture horizons in the Middle East coupled with promising trial data write the next chapter, making IBRX not just a ticker symbol, but a solid contender in cutting-edge biotechnology.

In summary, these developments offer a distinct outlook that marries market movements with scientific progress, embodying a stronger promise for ImmunityBio in the months to come. As traders continue to gauge the evolving landscape, the company’s trajectory remains compelling, poised for further strategic successes. As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.”

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”